AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19687032
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate (Group M) - i.v. bolus of 50 mg kg‐1 followed by a 15 mg kg‐1 h ‐1 continuous infusion
Trial: 17490862
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 to 2550 mg daily)
Trial: 2097486
Drug: Thiopental (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (300 mg)
Trial: 30612325
Drug: Probiotic supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplements for 4 months
Trial: 30612325
Drug: Placebo supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplements for 4 months
Trial: 26978327
Drug: Memantine ER
RxNorm normalized name: memantine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine ER (3 to 15 mg/day based on body weight)
Trial: 25982134
Drug: Fibrinogen concentrate
RxNorm normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen concentrate (30 mg kg(‐1)) with FIBTEM MCF trigger <13 mm (early substitution)
Trial: 25982134
Drug: Fibrinogen concentrate
RxNorm normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen concentrate (30 mg kg(‐1)) with FIBTEM MCF trigger <8 mm (conventional)
Trial: 25982134
Drug: Fibrinogen concentrate
RxNorm normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen concentrate (30 mg kg(‐1))
Trial: 19877063
Drug: alendronate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alendronate (10 mg/day)
Trial: 11778119
Drug: Sufentanil (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (intravenous and epidural)
Trial: 11778119
Drug: Sufentanil in
RxNorm normalized name: sufentanil Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil in combination with local anaesthetics (ropivacaine, bupivacaine)
Trial: 11778119
Drug: Sufentanil with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil with adjuvant drugs (clonidine, ketamine, adrenaline)
Trial: 11778119
Drug: Various administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Various administration methods (PCA, PCEA, fixed intervals doses, continuous infusion)
Trial: 9233591
Drug: Ifosphamide, etoposide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosphamide, etoposide and epirubicin (IVE) plus G-CSF
Trial: 9233591
Drug: Cyclophosphamide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide plus G-CSF
Trial: 8121964
Drug: Placebo substitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo substitution after Vitamin E treatment
Trial: 3117864
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium (metered-dose inhaler, 2 mg, four times a day, or capsules, 20 mg, four times a day)
Trial: 29285796
Drug: Weight-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based treatment (0.3 g/kg body weight)
Trial: 29285796
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment (15 g for adults, 10 g for children)
Trial: 25281992
Drug: Aripiprazole once-monthly
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole once-monthly 400mg
Trial: 25281992
Drug: Aripiprazole once-monthly
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole once-monthly 50mg
Trial: 23471546
Drug: Mirabegron 25
RxNorm normalized name: mirabegron 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 25 mg QD
Trial: 23471546
Drug: Mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 50 mg QD
Trial: 23471546
Drug: Mirabegron 100
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron 100 mg QD
Trial: 23471546
Drug: Mirabegron 200
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron 200 mg QD
Trial: 23471546
Drug: Mirabegron (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron (all doses)
Trial: 23471546
Drug: Mirabegron 100
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron 100 mg and 200 mg
Trial: 20855387
Drug: Hypothermia group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermia group (rectal temperature of 33.5°C for 72 hours)
Trial: 20855387
Drug: Normothermia group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normothermia group (rectal temperature of 37°C)
Trial: 12398952
Drug: High-calcium milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-calcium milk powder (800 mg of calcium)
Trial: 1722834
Drug: Honvan (diethylstilbestrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honvan (diethylstilbestrol diphosphate) 300 mg/day
Trial: 1722834
Drug: Estracyt (estramustine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estracyt (estramustine phosphate) 560 mg/day
Trial: 1722834
Drug: Prostal (chlormadinone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostal (chlormadinone acetate) 100 mg/day
Trial: 1722834
Drug: Castration plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Castration plus MTX (methotrexate) 20 mg/m2 every 2 weeks
Trial: 1722834
Drug: Castration plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Castration plus CPM (cyclophosphamide) 0.5-1 g/m2 every 3-4 weeks
Trial: 29348711
Drug: Topical ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ciprofloxacin ear drops plus oral placebo
Trial: 29348711
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral and topical ciprofloxacin
Trial: 24243927
Drug: Isotonic nasal
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotonic nasal saline spray
Trial: 18756344
Drug: Pentoxifylline 200
RxNorm normalized name: pentoxifylline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 200 mg per day for three days
Trial: 12806591
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 16 mg + Lisinopril 20 mg
Trial: 12806591
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg (maximum recommended dose)
Trial: 8840293
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (new model of hemodialysis potassium removal)
Trial: 8840293
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (standard hemodialysis)
Trial: 1611114
Drug: 1.3 g
RxNorm normalized name: glycerin 1.3 g RECTAL SUPPOSITORY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.3 g ethoglucid
Trial: 6560416
Drug: Technique 1
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technique 1 for administering subcutaneous low-dose heparin
Trial: 6560416
Drug: Technique 2
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technique 2 for administering subcutaneous low-dose heparin
Trial: 6560416
Drug: Technique 3
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technique 3 for administering subcutaneous low-dose heparin
Trial: 18497320
Drug: Continue anticoagulants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue anticoagulants for 9 additional months (RVT group)
Trial: 18497320
Drug: Stop anticoagulants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop anticoagulants (RVT group)
Trial: 12574190
Drug: 60‐65 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60‐65 mg iodide daily for 60 days (group A)
Trial: 12574190
Drug: 60‐65 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60‐65 mg iodide daily for 60 days (group B)
Trial: 12574190
Drug: 60‐65 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60‐65 mg iodide daily for 60 days (group C)
Trial: 12574190
Drug: 60‐65 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60‐65 mg iodide daily for 60 days (all groups)
Trial: 12574190
Drug: 60‐65 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60‐65 mg iodide daily for 60 days (group D)
Trial: 10417466
Drug: Nefopam (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam (0.15 mg.kg‐1)
Trial: 8745846
Drug: Peak flow
RxNorm normalized name: Peak Flow Meter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak flow measurements (weekly)
Trial: 1906004
Drug: Ro 19-6327
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 19-6327 (10 to 50 mg oral pre-dose)
Trial: 1906004
Drug: L‐deprenyl (tracer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐deprenyl (tracer alone)
Trial: 24569690
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interleukin-1 receptor antagonist (rhIL1ra, anakinra) at a dose of 100 mg subcutaneously once a day for 5 days
Trial: 24569690
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interleukin-1 receptor antagonist (rhIL1ra, anakinra)
Trial: 20329654
Drug: LOS/HCTZ (losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOS/HCTZ (losartan 50 mg/day + hydrochlorothiazide 12.5 mg/day)
Trial: 20329654
Drug: TEL/HCTZ (telmisartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEL/HCTZ (telmisartan 40 mg/day + hydrochlorothiazide 12.5 mg/day)
Trial: 20329654
Drug: CND/HCTZ (candesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CND/HCTZ (candesartan 8 mg/day + hydrochlorothiazide 12.5 mg/day)
Trial: 11707842
Drug: CHOP chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHOP chemotherapy (cyclophosphamide/doxorubicin/vincristine/prednisone)
Trial: 11707842
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factors added to CHOP chemotherapy
Trial: 11707842
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy followed by autologous stem cell transplantation
Trial: 11707842
Drug: New lymphoma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New lymphoma treatments with improved toxicity profiles
Trial: 7506168
Drug: nimesulide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nimesulide (300 mg/day)
Trial: 7506168
Drug: naproxen (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen (750 mg/day)
Trial: 26457580
Drug: Tesamorelin 2
RxNorm normalized name: tesamorelin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tesamorelin 2 mg subcutaneously daily for 6 months
Trial: 11744430
Drug: 3.0 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 g/day oral ganciclovir
Trial: 11744430
Drug: 4.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 g/day oral ganciclovir
Trial: 11744430
Drug: 6.0 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.0 g/day oral ganciclovir
Trial: 11744430
Drug: 5 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg/day IV ganciclovir
Trial: 2479303
Drug: terfenadine, 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terfenadine, 240 mg
Trial: 2479303
Drug: terfenadine, 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terfenadine, 120 mg
Trial: 31290344
Drug: ADT +
RxNorm normalized name: Antidepressant+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT + brexpiprazole 1-3 mg/day
Trial: 26255512
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at Zusanli (ST 36) combined with oral administration of Gexia Zhuyu decoction
Trial: 26255512
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment combined with oral administration of Gexia Zhuyu decoction
Trial: 21624752
Drug: Daily montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily montelukast 4 mg
Trial: 21624752
Drug: Intermittent montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent montelukast 4 mg
Trial: 19537367
Drug: Calcipotriol cream
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol cream applied to one side of the scalp and/or face for 12 weeks
Trial: 19537367
Drug: Ultrabase cream
RxNorm normalized name: Ultrasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrabase cream (placebo) applied to the other side for 12 weeks
Trial: 16423001
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg, amoxicillin 1 g, levofloxacin 500 mg, all given twice daily for 7 days (LAL)
Trial: 16423001
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg twice daily, metronidazole 400 mg thrice daily, bismuth subcitrate 120 mg and tetracycline 500 mg four times daily for 7 days (quadruple)
Trial: 16423001
Drug: Lansoprazole, amoxicillin
RxNorm normalized name: lansoprazole, amoxicillin and levofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole, amoxicillin plus levofloxacin (LAL)
Trial: 15229013
Drug: Concentrated intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated intravenous oxytocin plus low-dose vaginal PGE(2) 10 mg every 6 hours 4x
Trial: 8431124
Drug: Two 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 5% povidone‐iodine enemas and 24‐hour intravenous cefotaxime sodium and metronidazole hydrochloride (Group 1)
Trial: 8431124
Drug: Single injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injections of ceftriaxone sodium (1 g) and ornidazole (1 g) and two 5% povidone‐iodine enemas (Group 2)
Trial: 8431124
Drug: Saline enemas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline enemas and 24‐hour intravenous cefotaxime sodium and metronidazole hydrochloride (Group 3)
Trial: 8431124
Drug: Single injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injections of ceftriaxone sodium (1 g) and ornidazole (1 g) (Group 2)
Trial: 2887112
Drug: Misoprostol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (200 micrograms, four times daily for four weeks)
Trial: 23610100
Drug: Colestilan 9
RxNorm normalized name: colestilan
DrugBank: Colestilan chloride (DB11634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestilan 9 g/day
Trial: 23610100
Drug: Colestilan 12/15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestilan 12/15 g/day (pooled)
Trial: 23610100
Drug: Colestilan 3
RxNorm normalized name: colestilan
DrugBank: Colestilan chloride (DB11634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestilan 3 g/day
Trial: 23610100
Drug: Colestilan 6
RxNorm normalized name: colestilan
DrugBank: Colestilan chloride (DB11634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestilan 6 g/day
Trial: 23610100
Drug: Colestilan (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestilan (various doses)
Trial: 19128767
Drug: No specific
RxNorm normalized name: Oregano specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No specific analgesic intervention (control group)
Trial: 12723458
Drug: Immediate-release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release formulation of Fampridine (10 mg) in patients with spinal cord injury (n = 11)
Trial: 12723458
Drug: Control subjects
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control subjects (n = 6) receiving oral doses of 10, 15, 20, and 25 mg of Fampridine
Trial: 9043560
Drug: Tetracaine 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracaine 4% cream (30-minute application)
Trial: 9043560
Drug: Lidocaine-prilocaine cream
RxNorm normalized name: lidocaine / prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine-prilocaine cream (60-minute application)
Trial: 8438775
Drug: Beta-carotene (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (20 mg/d)
Trial: 28495562
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor with no predicted-active NRTIs
Trial: 28495562
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor and raltegravir
Trial: 23349733
Drug: L-carnitine (510
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (510 mg/day)
Trial: 14698699
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (carbamazepine, phenytoin, or valproate)
Trial: 3698521
Drug: Atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 100 mg daily + Nifedipine 30 mg daily
Trial: 31489188
Drug: Lemna minor
RxNorm normalized name: LEMNA MINOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lemna minor (20 g of protein)
Trial: 31489188
Drug: Green peas
RxNorm normalized name: green english pea allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green peas (20 g of protein)
Trial: 23669062
Drug: AM (Amlodipine)
RxNorm normalized name: Encora AM Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM (Amlodipine) 10 mg/day + OM (Olmesartan Medoxomil) 40 mg/day
Trial: 23669062
Drug: AM (Amlodipine)
RxNorm normalized name: Encora AM Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM (Amlodipine) 10 mg/day
Trial: 23669062
Drug: OM (Olmesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM (Olmesartan Medoxomil) 40 mg/day
Trial: 21515838
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (81 or 100 mg daily) in the diet-alone group
Trial: 21515838
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (81 or 100 mg daily) in the insulin group
Trial: 21515838
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (81 or 100 mg daily) in the OHA group
Trial: 21515838
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin in the insulin group
Trial: 21515838
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin in the OHA group
Trial: 21515838
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin in the diet-alone group
Trial: 17038073
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care with access to a depression care manager and Problem Solving Treatment for 12 months
Trial: 11558482
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of Atorvastatin vs Simvastatin
Trial: 8697067
Drug: Orlistat 50
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat 50 mg three times a day
Trial: 25562115
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (iCBT) program, 6-week, six-lesson
Trial: 23745303
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine hydrochloride 20 mL mixed with morphine 3 mg
Trial: 20873998
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of RF and topical steroid treatment
Trial: 10791374
Drug: Treatment guided
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment guided by plasma N‐BNP concentration (BNP group)
Trial: 8369005
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release diltiazem (180 mg)
Trial: 8369005
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release diltiazem (240 mg)
Trial: 8369005
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release diltiazem (300 mg)